Epithelial–mesenchymal transition in chemoradiation‐induced lung damage: Mechanisms and potential treatment approaches
Journal of Biochemical and Molecular Toxicology · 2024
DOI: 10.1002/jbt.23790 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2024. Verfasst von Mohamed J Saadh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Middle East University, Amman, Jordan. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Pulmonary Fibrosis, Chemoradiotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 287 Literaturangaben.
Abstract (Originalsprache)
Pulmonary injury is one of the key restricting factors for the therapy of malignancies with chemotherapy or following radiotherapy for chest cancers. The lung is a sensitive organ to some severely toxic antitumor drugs, consisting of bleomycin and alkylating agents. Furthermore, treatment with radiotherapy may drive acute and late adverse impacts on the lung. The major consequences of radiotherapy and chemotherapy in the lung are pneumonitis and fibrosis. Pneumonitis may arise some months to a few years behind cancer therapy. However, fibrosis is a long‐term effect that appears years after chemo/or radiotherapy. Several mechanisms such as oxidative stress and severe immune reactions are implicated in the progression of pulmonary fibrosis. Epithelial–mesenchymal transition (EMT) is offered as a pivotal mechanism for lung fibrosis behind chemotherapy and radiotherapy. It seems that pulmonary fibrosis is the main consequence of EMT after chemo/radiotherapy. Several biological processes, consisting of the liberation of pro‐inflammatory and pro‐fibrosis molecules, oxidative stress, upregulation of nuclear factor of κB and Akt, epigenetic changes, and some others, may participate in EMT and pulmonary fibrosis behind cancer therapy. In this review, we aim to discuss how chemotherapy or radiotherapy may promote EMT and lung fibrosis. Furthermore, we review potential targets and effective agents to suppress EMT and lung fibrosis after cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Pharmacy, Middle East University, Amman, Jordan.
- Department of Chemistry, School of Sciences, Jain (Deemed-to-be) University, Bengaluru, India.
- Department of Sciences, Vivekananda Global University, Jaipur, India.
- Medical Laboratories Techniques Department, AL-Mustaqbal University, Hillah, Iraq.
- School of Pharmacy-Adarsh Vijendra Institute of Pharmaceutical Sciences, Shobhit University, Gangoh, India.
- Department of Pharmacy, Arka Jain University, Jamshedpur, India.
Zitieren
APA
Saadh, M. J., Sharma, P., Naser, I. H., Kumar, A., Ravi Kumar, M., Rasulova, I., Mohammed, F., Allela, O. Q. B., Mohammed, W. K., Ahmed, N. M., Al-Ani, A. M., & Redhee, A. H. (2024). Epithelial–mesenchymal transition in chemoradiation‐induced lung damage: Mechanisms and potential treatment approaches. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.23790
Vancouver
Saadh MJ, Sharma P, Naser IH, Kumar A, Ravi Kumar M, Rasulova I, et al. Epithelial–mesenchymal transition in chemoradiation‐induced lung damage: Mechanisms and potential treatment approaches. Journal of Biochemical and Molecular Toxicology. 2024. doi:10.1002/jbt.23790
BibTeX
@article{Saadh2024,
author = {Saadh, Mohamed J and Sharma, Pawan and Naser, Israa Habeeb and Kumar, Abhishek and Ravi Kumar, M and Rasulova, Irodakhon and Mohammed, Faraj and Allela, Omer Qutaiba B and Mohammed, Wathiq Kh and Ahmed, Nahed Mahmood and Al-Ani, Ahmed Muzahem and Redhee, Ahmed Huseen},
title = {Epithelial–mesenchymal transition in chemoradiation‐induced lung damage: Mechanisms and potential treatment approaches},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2024},
doi = {10.1002/jbt.23790}
}
EUVIMED